Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study Meeting Abstract
| Authors: | Marth, C.; Moore, R.; Bidzinski, M.; Pignata, S.; Ayhan, A.; Rubio, M. J.; Beiner, M.; Hall, M.; Vulsteke, C.; Braicu, E. I.; Sonoda, K.; Wu, X.; Frentzas, S.; Mattar, A.; McKenzie, J.; Yao, L.; Khemka, V.; Orlowski, R.; Gilbert, L.; Makker, V. |
| Abstract Title: | Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: Primary results of the phase III ENGOT-En9/LEAP-001 study |
| Meeting Title: | Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer |
| Journal Title: | Gynecologic Oncology |
| Volume: | 190 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2024 Mar 15-18 |
| Meeting Location: | San Deigo, CA |
| ISSN: | 0090-8258 |
| Publisher: | Elsevier Inc. |
| Date Published: | 2024-11-01 |
| Start Page: | S63 |
| End Page: | S64 |
| Language: | English |
| ACCESSION: | WOS:001330731400085 |
| DOI: | 10.1016/j.ygyno.2024.07.094 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 22 [LBA] -- Source: Wos |
